SEC Form 4 · accession 0001562180-17-003346
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A Orwin
Director
Period of report
Oct 26, 2017
Accepted (ET)
Oct 27, 2017 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 27, 2017 | M | 5,000 | $10.47 | A | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.47 | Oct 26, 2017 | A | 25,000 | A | Oct 26, 2018 | Oct 26, 2027 | Common Stock | 25,000 | 25,000 | D |
| Restricted Stock UnitsF2 | $0.00 | Oct 26, 2017 | A | 5,000 | A | Oct 26, 2018 | — | Common Stock | 5,000 | 5,000 | D |
| Restricted Stock UnitsF3 | $0.00 | Oct 27, 2017 | M | 5,000 | D | Oct 27, 2017 | — | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on October 27, 2016 as a result of the vesting of all such RSUs.
- F2RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 26, 2018, subject to continued service on Array's board of directors.
- F3RSUs awarded to the reporting person on October 27, 2016 for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vested and were settled in stock on October 27, 2017.